US Continuous Glucose Monitoring Market to Grow Fast Owing to Sensor Advances

US Continuous Glucose Monitoring Market to Grow Fast Owing to Sensor Advances

Continuous glucose monitoring (CGM) systems provide real-time detection of glucose levels, offering diabetic patients and healthcare providers accurate, continuous insights to optimize insulin therapy and daily management. These wearable devices comprise sensors, transmitters, and display units, leveraging minimally invasive or non-invasive techniques to track glycemic fluctuations around the clock. Advantages include improved glycemic control, reduced hypoglycemia risk, and enhanced patient compliance compared to traditional finger-stick methods.

Rising diabetes prevalence, emphasis on personalized medicine, and integration of CGM data with mobile health apps are driving United States of America Continuous Glucose Monitoring Market demand. Detailed market research and market insights highlight evolving competitive dynamics and patient-centric strategies. As technology evolves, sensor accuracy, wear time, and connectivity features continue to improve, supporting telemedicine and remote monitoring protocols. The robust pipeline of next-generation CGM products underscores strong market growth potential, while regulatory approvals and reimbursement policies further expand accessibility.

The United States of America Continuous Glucose Monitoring Market is estimated to be valued at USD 652.2 Mn in 2025 and is expected to reach USD 1177.0 Mn by 2032, growing at a compound annual growth rate (CAGR) of 8.8% from 2025 to 2032.

Key Takeaways

Key players operating in the United States of America Continuous Glucose Monitoring Market are:

-Abbott

-Dexcom, Inc.

-Medtronic

-Senseonics, Inc.

-F. Hoffmann-La Roche Ltd

Each of these market players leverages robust R&D pipelines and strategic collaborations to strengthen their market share. Abbott’s FreeStyle Libre series, Dexcom’s G6 and G7 systems, Medtronic’s Guardian™ Connect, Senseonics’s Eversense implantable sensors, and Roche’s Accu-Chek platforms have established strong footholds in both consumer and clinical segments.

Growing demand: The United States’ soaring diabetes incidence is a primary market driver, fueling significant market growth for CGM solutions. Patient preference for minimally invasive monitoring, coupled with increasing awareness of the benefits of continuous glucose data, is expanding the market size. Reimbursement policies and government initiatives targeting diabetes management further stimulate uptake. Market research indicates rising demand in both adult and pediatric segments, reflecting shifting market dynamics toward proactive disease control.

Technological advancement: Rapid innovation in sensor accuracy, extended wear durations, and integration with cloud-based platforms define current market trends. Next-generation CGM devices are leveraging artificial intelligence and predictive analytics to deliver personalized alerts and trend forecasting. Bluetooth-enabled transmitters and smartphone compatibility facilitate seamless data sharing between patients and clinicians, enhancing telehealth capabilities. As interoperability standards evolve, CGM technology is poised to integrate with insulin pumps and digital health ecosystems, strengthening the overall market forecast.

Market trends

One prominent trend is the growing adoption of interoperable CGM-insulin pump systems, enabling automated insulin delivery and tighter glycemic control. This closed-loop approach integrates CGM sensors with insulin pumps via sophisticated algorithms, marking a shift toward fully automated diabetes management. Second, the rise of digital therapeutics and remote monitoring is reshaping diabetes care. Cloud-based platforms collect CGM data in real time, powering telemedicine consultations and population health management. Healthcare providers leverage these market insights to tailor treatment plans, while payers support remote monitoring to reduce hospitalizations and lower costs. Additionally, hybrid devices combining CGM with smart insulin pens are emerging, broadening the market segments and enhancing patient adherence.

Market Opportunities
The growing geriatric population presents a significant opportunity for CGM manufacturers, as older adults increasingly seek non-invasive monitoring solutions to manage age-related diabetes complications. Customized CGM systems designed for ease of use and extended wear can capture this underserved segment, driving business growth. A second opportunity lies in expanding reimbursement frameworks and value-based care models. As insurers and government agencies recognize CGM’s cost-saving potential by reducing acute events, broader coverage can unlock new market opportunities and revenue streams. Partnerships between device companies and healthcare providers to develop bundled care packages—combining CGM hardware with digital coaching—offer additional avenues for market expansion. Furthermore, the entry of software-as-a-medical-device (SaMD) platforms can enhance market scope through advanced data analytics services.

Impact of COVID-19 on United States of America Continuous Glucose Monitoring Market Growth

Prior to the pandemic, the United States of America Continuous Glucose Monitoring Market demonstrated steady market growth driven by rising diabetes prevalence and technological innovation. Market dynamics included gradual adoption of wearable sensors and integration with mobile applications, supported by favorable reimbursement policies. Market research had highlighted solid market drivers such as patient preference for minimally invasive monitoring and increasing physician awareness. However, industry trends before COVID-19 were characterized by moderate market challenges, including device accuracy concerns and high upfront costs.

When COVID-19 hit, the landscape shifted dramatically. Lockdowns and fear of virus exposure limited routine clinic visits, disrupting traditional supply chains for sensors and transmitters. Many patients postponed non-emergency consultations, leading to temporary downturn in device placements. Market insights during the height of the outbreak revealed that remote monitoring became a critical market opportunity. Healthcare providers accelerated virtual consultations, driving demand for cloud-compatible continuous glucose monitoring. While initial restrictions applied pressure on distribution channels, innovative companies expanded direct-to-patient shipping, mitigating market restraints.

Post-pandemic, this market found new momentum. Telehealth integration emerged as a significant market driver, enhancing patient engagement and compliance. Market trends now emphasize data analytics platforms and AI-based predictive alerts. Ongoing market analysis indicates growing collaboration between software developers and medical device manufacturers to improve predictive accuracy. Future strategies must prioritize robust telehealth partnerships, strengthen supply chain resilience, and offer flexible pricing models to address reimbursement uncertainties. Embracing patient-centric support services and expanding education initiatives will sustain market opportunities. By aligning with evolving healthcare delivery models and leveraging lessons from the COVID-19 era, stakeholders can unlock further market growth and expand the market scope for continuous glucose monitoring solutions across the United States.

Geographical Regions Where the Market Is Concentrated in the United States

Within the United States of America Continuous Glucose Monitoring Market, value concentration tends to cluster in regions with high population densities and advanced healthcare infrastructure. The Northeast—especially states like New York and Massachusetts—accounts for a substantial share of device installations and aftermarket sensor sales. This region benefits from leading academic medical centers that conduct cutting-edge clinical trials and early adopter programs. As a result, market share in the Northeast reflects robust physician endorsement and strong payer support.

The West Coast follows closely, driven by California’s large diabetic population and strong presence of medical technology hubs. Here, extensive venture capital investment has accelerated development of innovative market segments such as implantable sensors and closed-loop insulin delivery systems. The Pacific Northwest, with its concentration of healthcare startups, also commands a significant portion of market revenue. This concentration is a direct outcome of favorable state-level reimbursement policies and proactive public health campaigns promoting continuous monitoring.

In the South, states such as Texas and Florida demonstrate growing demand fueled by rising diabetes prevalence and expanding telehealth networks. Although still catching up to the Northeast in per-capita adoption, the southern region is witnessing rapid uptake due to large-scale awareness programs and partnerships between payers and device providers. The Midwest—anchored by Illinois and Michigan—shows consistent growth, supported by regional manufacturing facilities and established distribution channels. Academic consortia in the Great Lakes area also contribute to continuous glucose monitoring education initiatives, bolstering usage.

Overall, this market’s value concentration aligns with regional healthcare sophistication, local market dynamics, and level of policy support. Stakeholders focusing on high-density urban areas and technology-forward states can maximize returns, while emerging pockets in the South and Midwest present untapped market opportunities for expansion.

Fastest Growing Region in the United States of America Continuous Glucose Monitoring Market

When evaluating recent market trends, the Western United States emerges as the fastest growing region for continuous glucose monitoring adoption. California stands at the forefront, propelled by a high incidence of diabetes, robust telehealth infrastructure, and a dense network of endocrinology specialists. Market analysis shows that the region’s market growth outpaces national averages, thanks to early integration of digital health platforms and proactive state-level reimbursement frameworks.

Within this Western corridor, the Pacific Northwest—encompassing Washington and Oregon—has experienced a marked acceleration in CGM usage. Enhanced public awareness campaigns and collaborations between tech startups and healthcare systems have created unique market opportunities. Patients in urban centers such as Seattle and Portland benefit from seamless integration of sensor data into electronic medical records, driving engagement and adherence. The region’s vibrant innovation ecosystem fosters rapid product iterations and pilot programs that test next-generation sensor technologies, contributing to elevated market share.

The Southwest, particularly Arizona and Nevada, also shows impressive momentum. Increased investment in remote patient monitoring during the pandemic laid the groundwork for sustained expansion. Market drivers in this desert region include lower state taxes for medical device operations, which attract distribution centers and research partnerships. These factors, combined with targeted outreach to rural populations via telemedicine, have unlocked new customer segments and revenue streams.

As the Western region continues to lead, market forecast models predict further acceleration driven by ongoing digital health collaborations and patient preference for mobile-enabled monitoring. Stakeholders focusing on this region’s receptive payer environment and tech-savvy population will capitalize on the fastest growing market dynamics, establishing a strong foothold before similar uptake occurs in other parts of the country.

‣ Get More Insights On: United States of America Continuous Glucose Monitoring Market

‣ Get this Report in Japanese Language: アメリカ合衆国の持続血糖測定市場

‣ Get this Report in Korean Language: 미국연속포도당모니터링시장

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)